Capri EGM Build-to-Suit Program Acquires Life Science Real Estate Asset for Company Manufacturing Antibodies for Department of Defense and mRNA for COVID-19 Vaccine

Capri EGM, an investment company specializing in corporate build-to-suit and sale leaseback financing, and the acquisition of income generating life science, R&D, and logistics real estate, has funded and acquired a newly constructed, state-of-the-art lab and R&D facility for National Resilience Inc (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. 

UF startup Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the Lab & Research facility, has recently been awarded contract valued as much as $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT). Resilience also has a multi-year agreement to produce mNRA for Moderna’s Covid-19 vaccine, a strategic multi-year R&D alliance with Harvard University to develop complex medicines, and a multi-product biomanufacturing development agreement with Takeda supporting their plasma-derived medicines portfolio.

The Resilience Lab & Research build-to-suit is strategically located in North Florida’s Research and Life Science cluster near the University of Florida and the University of Florida’s Innovate Sid Martin Biotech Incubator, the #1 ranked biotech incubator globally. The property is surrounded by a variety of other symbiotic high-tech uses including bioscience and medical product development, pharma compounding, and R&D firms. The proximity to the University of Florida, a top 5 ranked public university, provides a pipeline of talent and research opportunities.

Read more about Capri EGM Build-To-Suit Program Acquires Life Science Real Estate Asset for Company Manufacturing Antibodies for Department of Defense and mRNA for COVID-19 Vaccine